

1<sup>st</sup> April 2025

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex, Bandra  
(East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

Dear Sir / Madam,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Dear Sir/Ma’am,

Pursuant to Regulation 30 of SEBI Listing Regulations, 2015, this is to intimate the Stock Exchanges about the commencement of commercial production of Sevoflurane at the Company’s facility located at Digwal, Telangana, India.

This was achieved by creating capacity for Sevoflurane manufacture at the Digwal facility in addition to existing capabilities at the Company’s facility at Bethlehem, Pennsylvania, USA.

This would boost the Company’s capability to also tap into Inhalation Anesthesia opportunities in the ROW markets in addition to the USA markets.

Kindly take the above on record.

Yours faithfully,  
For **Piramal Pharma Limited**

**Tanya Sanish**  
**Company Secretary**

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000; Email: [shareholders.ppl@piramal.com](mailto:shareholders.ppl@piramal.com)

[piramalpharma.com](http://piramalpharma.com)